STOCK TITAN
  1. Home
  2. Sec-filings
  3. KPHMW
  4. [Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity

Kiora Pharmaceuticals (NASDAQ: KPRX) CFO granted new stock and option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kiora Pharmaceuticals CFO Melissa Tosca received new equity awards as part of her compensation. She was granted an option to buy 13,067 shares of Common Stock at an exercise price of $1.98 per share, along with 6,533 shares of restricted Common Stock.

The restricted stock will vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029, contingent on continued service. The stock option vests one-third on April 1, 2027, with the remaining two-thirds vesting monthly over the following two years, and expires on April 1, 2036. After these grants, Tosca directly holds 27,904 Common shares and 13,067 option shares.

Positive

  • None.

Negative

  • None.
Insider Tosca Melissa
Role CFO
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 13,067 $0.00 --
Grant/Award Common Stock 6,533 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 13,067 shares (Direct); Common Stock — 27,904 shares (Direct)
Footnotes (1)
  1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1 , 2027, April 1 , 2028 and April 1 , 2029, subject to the reporting person's continuous service through each such vesting date. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tosca Melissa
(Last) (First) (Middle)
C/O KIORA PHARMACEUTICALS, INC.
169 SAXONY RD., SUITE 212
(Street)
ENCINITAS CA 92024
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/06/2026 A 6,533(1) A $0 27,904 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.98 03/06/2026 A 13,067 04/01/2027(2) 04/01/2036 Common Stock 13,067 $0 13,067 D
Explanation of Responses:
1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1 , 2027, April 1 , 2028 and April 1 , 2029, subject to the reporting person's continuous service through each such vesting date.
2. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.
Remarks:
/s/ Melissa Tosca 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Kiora Pharmaceuticals (KPRX) CFO Melissa Tosca receive?

Melissa Tosca received 6,533 shares of restricted Common Stock and an option for 13,067 Common shares at an exercise price of $1.98 per share, structured as compensation under Kiora Pharmaceuticals’ 2024 Equity Incentive Plan with multi‑year vesting conditions.

How do the new stock options for Kiora (KPRX) CFO Melissa Tosca vest?

The option for 13,067 shares vests one-third on April 1, 2027, with the remaining two-thirds vesting monthly on the first day of each month over two years, subject to Melissa Tosca’s continuous service through each vesting date under the company’s equity plan.

What is the vesting schedule for Melissa Tosca’s restricted Kiora (KPRX) shares?

The 6,533 restricted shares vest in three equal tranches on April 1, 2027, April 1, 2028, and April 1, 2029, provided Melissa Tosca remains in continuous service with Kiora Pharmaceuticals through each scheduled vesting date.

What are Melissa Tosca’s Kiora (KPRX) holdings after the reported Form 4 transactions?

Following the reported grants, Melissa Tosca directly holds 27,904 shares of Kiora Pharmaceuticals Common Stock and 13,067 option shares. These positions reflect newly awarded restricted stock and stock options granted under the company’s 2024 Equity Incentive Plan on the reported transaction date.

When do Melissa Tosca’s newly granted Kiora (KPRX) stock options expire?

The newly granted option to purchase 13,067 Kiora Pharmaceuticals Common shares expires on April 1, 2036. This long-dated expiration allows up to ten years from the grant’s vesting commencement for potential exercise, assuming ongoing satisfaction of the continuous service requirements.

Is Melissa Tosca’s Form 4 for Kiora (KPRX) a market buy or a compensation grant?

The Form 4 reflects compensation-related grants, not open‑market purchases. It shows an award of restricted stock and a stock option under Kiora Pharmaceuticals’ 2024 Equity Incentive Plan, both recorded with transaction code “A” for grant or award acquisitions.